Current Hepatitis Reports

, Volume 7, Issue 2, pp 64–71 | Cite as

Optimizing therapy in treatment-naïve genotype 1 patients

Article

Abstract

With the current standard dose and duration of pegylated interferon (PEG-IFN) and ribavirin (RBV), a sustained virologic response (SVR) is obtained in about 40% to 45% of patients with hepatitis C virus genotype 1. Few baseline characteristics can be modified to enhance response rates, so the focus of recent studies has been on whether increasing the dose and duration of treatment can improve SVR rates. Emerging data support consideration of higher-dose RBV and possibly higher doses of PEG-IFN. Additionally, for those not achieving a complete early virologic response, extending treatment from 48 to 72 weeks reduces relapse rates and improves sustained responses. Adherence remains an important “on-treatment factor” influencing responses, but studies are inconsistent in terms of what the “critical” cutoff for dose reductions is. At present, the best strategy to maximize SVR rates for genotype 1 and other “difficult-to-treat” populations includes determining whether any baseline factors can be modified before treatment, maximizing adherence, considering use of higher drug doses, and adjusting treatment duration based on early virologic responses.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Armstrong G, Wasley A, Simard E, et al.: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705–714.PubMedGoogle Scholar
  2. 2.
    Nainan OV, Alter MJ, Kruszon-Moran D, et al.: Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006, 131:478–484.PubMedCrossRefGoogle Scholar
  3. 3.
    Bruno S, Stroffolini T, Colombo M, et al.: Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579–587.PubMedCrossRefGoogle Scholar
  4. 4.
    Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.PubMedCrossRefGoogle Scholar
  5. 5.
    Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadziyannis S, Sette HJ, Morgan T, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346–355.PubMedGoogle Scholar
  7. 7.
    Layden-Almer JE, Ribeiro RM, Wiley T, et al.: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37:1343–1350.PubMedCrossRefGoogle Scholar
  8. 8.
    Muir A, Bornstein J, Killenberg P, Atlantic Coast Hepatitis Treatment Group: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004, 350:2265–2271.PubMedCrossRefGoogle Scholar
  9. 9.
    Jeffers L, Cassidy W, Howell C, et al.: Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39:1702–1708.PubMedCrossRefGoogle Scholar
  10. 10.
    Conjeevaram HS, Fried MW, Jeffers LJ, et al.: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470–477.PubMedCrossRefGoogle Scholar
  11. 11.
    Rosen HR, Weston SJ, Im K, et al.: Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007, 46:350–358.PubMedCrossRefGoogle Scholar
  12. 12.
    Bonacini M, Groshen MD, Yu MC, et al.: Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 2001, 96:2438–2441.PubMedCrossRefGoogle Scholar
  13. 13.
    Cheung RC, Currie S, Shen H, et al.: Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005, 100:2186–2193.PubMedCrossRefGoogle Scholar
  14. 14.
    Muñoz H, Arroyo J, Torres E, et al.: Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C. P R Health Sci J 2004, 23(Suppl):61–67.PubMedGoogle Scholar
  15. 15.
    Thomas DL: The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008, 59:473–485.PubMedCrossRefGoogle Scholar
  16. 16.
    Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562–569.PubMedCrossRefGoogle Scholar
  17. 17.
    Voigt E, Schulz C, Klausen G, et al.: Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J Infect 2006, 53:36–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848.PubMedCrossRefGoogle Scholar
  19. 19.
    Chung R, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451–459.PubMedCrossRefGoogle Scholar
  20. 20.
    Torriani F, Rodriguez-Torres M, Rockstroh J, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438–450.PubMedCrossRefGoogle Scholar
  21. 21.
    Soriano V, Miralles C, Berdun MA, et al.: Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther 2007, 12:469–476.PubMedGoogle Scholar
  22. 22.
    Munez M, Miralles C, Berdun MA, et al.: Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007, 23:972–982.CrossRefGoogle Scholar
  23. 23.
    Negro F: Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006, 12:6756–6765.PubMedGoogle Scholar
  24. 24.
    Poynard T, Ratziu V, McHutchison J, et al.: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Patton HM, Patel K, Behling C, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484–490.PubMedCrossRefGoogle Scholar
  26. 26.
    Harrison SA, Brunt EM, Qazi RA, et al.: Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3:604–609.PubMedCrossRefGoogle Scholar
  27. 27.
    Conjeevaram HS, Kleiner DE, Everhart JE, et al.: Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007, 45:80–87.PubMedCrossRefGoogle Scholar
  28. 28.
    Davis G, Yuan JB, McHutchison JG: Early virologic response to treatment with pegylated interferon a-2b and ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645–652.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferenci P, Fried MW, Shiffman ML, et al.: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43:425–433.PubMedCrossRefGoogle Scholar
  30. 30.
    Drusano GL, Preston SL: A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004, 189:964–970.PubMedCrossRefGoogle Scholar
  31. 31.
    Berg T, von Wagner M, Nasser S, et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086–1097.PubMedCrossRefGoogle Scholar
  32. 32.
    Sanchez-Tapias JM, Diago M, Escartin P, et al.: Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451–460.PubMedCrossRefGoogle Scholar
  33. 33.
    Pearlman BL, Ehleben C, Saifee S: Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46:1688–1694.PubMedCrossRefGoogle Scholar
  34. 34.
    Mangia A, Minerva N, Bacca D, et al.: Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008, 47:43–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Ferenci P, Laferi H, Scherzer M, et al.: Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV genotype 1 or 4. Hepatology 2007, 46:A1301.CrossRefGoogle Scholar
  36. 36.
    Rodriguez-Torres M, Sulkowski M, Chung R, et al.: Association of pre-treatment and on-treatment factors with rapid virologic response in HCV genotype 1 infected patients treated with peginterferon alfa-2a/ribavirin. Hepatology 2007, 46:A1305.Google Scholar
  37. 37.
    Yu JW, Wang GQ, Sun LJ, et al.: Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007, 22:832–836.PubMedCrossRefGoogle Scholar
  38. 38.
    Jensen DM, Morgan TR, Marcellin P, et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954–960.PubMedCrossRefGoogle Scholar
  39. 39.
    Jacobson IM, Brown RS Jr, Freilich B, et al.: Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46:971–981.PubMedCrossRefGoogle Scholar
  40. 40.
    Shiffman ML, Salvatore J, Hubbard S, et al.: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007, 46:371–379.PubMedCrossRefGoogle Scholar
  41. 41.
    Rodriguez-Torres M, Sulkowski M, Chung RT, et al.: Association of pre-treatment and on-treatment factors with rapid virologic response in HCV genotype 1 infected patients treated with peginterferon alfa-2a/ribavirin [abstract 1305]. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.Google Scholar
  42. 42.
    Roberts S, Weltman M, Crawford D, et al.: Rapid and early virologic response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study [abstract 54]. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.Google Scholar
  43. 43.
    McHutchison J, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response to genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069.PubMedCrossRefGoogle Scholar
  44. 44.
    Reddy KR, Shiffman ML, Morgan TR, et al.: Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124–129.PubMedCrossRefGoogle Scholar
  45. 45.
    Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922–924.PubMedCrossRefGoogle Scholar
  46. 46.
    Shiffman M, Ghany M, Morgan T, et al.: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103–112.PubMedCrossRefGoogle Scholar
  47. 47.
    Afdhal N, Dieterich D, Pockros P, et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:302–311.CrossRefGoogle Scholar
  48. 48.
    Pockros PJ, Shiffman ML, Schiff ER, et al.: Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004, 40:1450–1458.PubMedCrossRefGoogle Scholar
  49. 49.
    McHutchison JG, Dusheiko G, Shiffman ML, et al.: Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357:2227–2236.PubMedCrossRefGoogle Scholar
  50. 50.
    Cacoub P, Goderel I, Morlat P, et al.: Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. Epidemiol Infect 2005, 133:305–314.PubMedCrossRefGoogle Scholar
  51. 51.
    Smith SR, Wahed AS, Kelley SS, et al.: Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007, 41:1116–1123.PubMedCrossRefGoogle Scholar
  52. 52.
    Zeuzem S, Buti M, Ferenci P, et al.: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97–103.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.University of CaliforniaSan FranciscoUSA

Personalised recommendations